![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 5 of 5. This is the beginning of the thread.
Posted by ed_uk2010 on February 29, 2012, at 16:59:41
For SLS,
Forest reported yesterday that they expect to file NDAs for cariprazine (for bipolar mania and schizophrenia) later in 2012. Good news I think.
Posted by SLS on February 29, 2012, at 17:23:25
In reply to Cariprazine, posted by ed_uk2010 on February 29, 2012, at 16:59:41
> For SLS,
>
> Forest reported yesterday that they expect to file NDAs for cariprazine (for bipolar mania and schizophrenia) later in 2012. Good news I think.
Thanks, Ed. I would love to switch over from Abilify to cariprazine if it means reducing metabolic side effects.
- Scott
Posted by b2chica on March 1, 2012, at 11:56:03
In reply to Re: Cariprazine » ed_uk2010, posted by SLS on February 29, 2012, at 17:23:25
Here's what i found in an article from Jan 2010.
Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor AntagonistPartial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
Article from Jan 21, 2010
So it seems that Cariprazine is most like Abilify. Except with the affinity for D3 receptors. also low affinity for H1 (and 5-ht2c)than abilify.
Maybe something else that wont make us sleepy, and maybe MAYBE less weight gain, eh?
it is anticipated that the clinical effects of cariprazine caused by 5-HT2A receptor activity would be considerably less.
"...suggesting that cariprazine may have low propensity for causing extrapyramidal symptoms."
Positive results in phase II of bipoar mania and schizophrenia trials.
-Now as ed stated positive results in 2 phase III trials. however these may have only included schizophrenia.BUT is also being investigated in bipolar depression and as adjunct tx for MDD.
**************************
as i am a zyprexa fan i would have liked to have read that it had a little more in common with olanzipine. However, perhaps with the more dopamine affinities and less 5ht2 there will be less of the bad and more of the good from all the AP's?also it mentioned something about improving cognition? or maybe that was another article. i cant remember.
Let us know when they are looking at making it available in U.S.
i thought they said sometime in 2012? could that be right? but not sure if that meant in U.S. or other countries too (or instead of).was a little confused of the origin of study. it first looked like came from Hungary, but then maybe a lab in california took over for phase II and III studies?
**************
keep us updated!B2c.
Posted by SLS on March 1, 2012, at 13:27:28
In reply to Re: Cariprazine, posted by b2chica on March 1, 2012, at 11:56:03
Hi B2C
Good information. Thanks.
Abilify is actually a partial agonist of D3 receptors as well as D2 receptors.
Thanks for pointing out the histamine thing. It would be nice to lose the weight. Fortunately, I don't feel sedated with Abilify.
- Scott
> Here's what i found in an article from Jan 2010.
>
> Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor AntagonistPartial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
> Article from Jan 21, 2010
>
>
> So it seems that Cariprazine is most like Abilify. Except with the affinity for D3 receptors. also low affinity for H1 (and 5-ht2c)than abilify.
> Maybe something else that wont make us sleepy, and maybe MAYBE less weight gain, eh?
>
>
> it is anticipated that the clinical effects of cariprazine caused by 5-HT2A receptor activity would be considerably less.
> "...suggesting that cariprazine may have low propensity for causing extrapyramidal symptoms."
>
>
> Positive results in phase II of bipoar mania and schizophrenia trials.
> -Now as ed stated positive results in 2 phase III trials. however these may have only included schizophrenia.
>
> BUT is also being investigated in bipolar depression and as adjunct tx for MDD.
>
>
> **************************
> as i am a zyprexa fan i would have liked to have read that it had a little more in common with olanzipine. However, perhaps with the more dopamine affinities and less 5ht2 there will be less of the bad and more of the good from all the AP's?
>
> also it mentioned something about improving cognition? or maybe that was another article. i cant remember.
>
> Let us know when they are looking at making it available in U.S.
> i thought they said sometime in 2012? could that be right? but not sure if that meant in U.S. or other countries too (or instead of).
>
> was a little confused of the origin of study. it first looked like came from Hungary, but then maybe a lab in california took over for phase II and III studies?
>
> **************
> keep us updated!
>
> B2c.
Posted by b2chica on March 1, 2012, at 16:18:48
In reply to Re: Cariprazine » b2chica, posted by SLS on March 1, 2012, at 13:27:28
i never felt sedated with abilify either, infact just the opposite. i got extremely aggitated and angry. i wonder would that reaction be because of D3, 5ht2 or H1? correlation? i'm trying to determine if this wouold be one for myself to try.
i do quite well on zyprexa though a little zombie-ish and quite rotund. So i was wishing it would be closer to zyprexa than abilify.
i'm worried that if i were try this new one that i would react even worse than i did on abilify?what do you think Scott?
if one did poorly on abilify would it be worth trying out?
i always felt that it was something inthe dopamine or Ach in zyprexa that was my key. not sure why. but that's why when i heard it effected D3 i thought it was something really new. didnt realize that abilify hit on D3 also...b2c.
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.